Figure 11.

In vivo dynamic measurement of Aβ plaques after treatment with HJ6.3. Fifty microliters of fluorescently labeled DyLight 594-apoE antibody HJ6.3 or DyLight 594-anti-HA control antibody (1.0 mg/ml) were topically applied to the brain surface of 5- to 7-month-old APP/PS1 mice. Plaques were monitored by two-photon microscopy. A, Representative in vivo images of the fluorescently labeled DyLight 594-HJ6.3 and methoxy-XO₄ the day of application (t = 0) or 14 d after (t = 14 d), showing that the plaque that got cleared (yellow arrow) was previously labeled by DyLight 594-HJ6.3, as opposed to nonlabeled plaque (white arrow). Scale bar, 100 μm. B, Contingency table summarizing the number of “absent,” “stable,” and “new” plaques according to their initial binding with anti-apoE HJ6.3 and anti-HA antibodies. C, Representative in vivo images of the fluorescently labeled DyLight 594-HJ6.3 and methoxy-XO₄ the day of application (t = 0) or 14 d after (t = 14 d), showing that the size of HJ6.3-labeled plaque decreased after topical application of labeled HJ6.3 (yellow arrow), as opposed to nonlabeled plaque (indicated by white arrow). Scale bar, 100 μm. D, Graph bar indicating the size ratio between day 0 and day 14 after topical application of the control antibody or the anti-apoE antibody HJ6.3 (n = 3/group; *p < 0.05, ***p < 0.001 for one-way ANOVA followed by post hoc Tukey test and p < 0.0001 for χ² test).